Free Trial

Aptose Biosciences (APS) Competitors

Aptose Biosciences logo
C$2.50 +0.20 (+8.70%)
As of 07/11/2025 03:55 PM Eastern

APS vs. BCT, IPA, TH, SCYB, COM, NVH, IGX, ONC, PDP, and COV

Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Theratechnologies (TH), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Oncolytics Biotech (ONC), Pediapharm (PDP), and Covalon Technologies (COV). These companies are all part of the "biotechnology" industry.

Aptose Biosciences vs. Its Competitors

Aptose Biosciences (TSE:APS) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

15.1% of Aptose Biosciences shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aptose Biosciences' return on equity of 1,017.48% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptose BiosciencesN/A 1,017.48% -136.29%
BriaCell Therapeutics N/A N/A N/A

BriaCell Therapeutics has a consensus price target of C$15.00, suggesting a potential upside of 41.51%. Given BriaCell Therapeutics' higher probable upside, analysts plainly believe BriaCell Therapeutics is more favorable than Aptose Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptose Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
BriaCell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A-C$154.69M-C$5.02-0.50
BriaCell TherapeuticsN/AN/AN/A-C$0.38-28.19

In the previous week, BriaCell Therapeutics had 1 more articles in the media than Aptose Biosciences. MarketBeat recorded 2 mentions for BriaCell Therapeutics and 1 mentions for Aptose Biosciences. Aptose Biosciences' average media sentiment score of 0.00 beat BriaCell Therapeutics' score of -0.27 indicating that Aptose Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aptose Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BriaCell Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Aptose Biosciences beats BriaCell Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Aptose Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APS vs. The Competition

MetricAptose BiosciencesBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$107.65MC$129.25MC$5.62BC$6.20B
Dividend Yield0.39%3.74%5.24%6.72%
P/E Ratio-0.503.4728.1350.47
Price / SalesN/A4,141.03428.631,211.67
Price / Cash1.6013.1937.4683.29
Price / Book-2.7342.088.044.70
Net Income-C$154.69M-C$92.15MC$3.18BC$301.20M
7 Day Performance106.61%1.32%3.62%1.04%
1 Month Performance5.49%4.35%4.05%4.03%
1 Year Performance-91.13%174.73%30.00%25.97%

Aptose Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APS
Aptose Biosciences
N/AC$2.50
+8.7%
N/A-91.6%C$107.65MN/A-0.5031Gap Down
High Trading Volume
BCT
BriaCell Therapeutics
N/AC$10.60
-3.8%
C$15.00
+41.5%
+0.0%C$168.68MN/A-28.195News Coverage
IPA
ImmunoPrecise Antibodies
N/AC$6.50
+0.8%
N/A+0.0%C$162.08MC$19.47M-7.3080News Coverage
Gap Down
TH
Theratechnologies
N/AC$3.22
-0.9%
N/A+120.5%C$102.74MC$52.22M-36.45103
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%
N/A+0.0%C$102.38MN/A0.00N/AHigh Trading Volume
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/A0.00N/A
NVH
Novoheart
N/AC$0.53
+1.9%
N/A+0.0%C$99.98MC$423.50K-13.95N/A
IGX
IntelGenx Technologies
N/AC$0.58
+1.8%
N/A+0.0%C$87.32MC$1.75M-7.442,050Gap Up
ONC
Oncolytics Biotech
1.0649 of 5 stars
C$1.07
+2.9%
C$3.50
+227.1%
+14.3%C$82.47MN/A-2.9829Analyst Revision
PDP
Pediapharm
N/AC$0.30
+1.7%
N/A+0.0%C$66.36MC$11.16M-4.11N/A
COV
Covalon Technologies
N/AC$2.37
-1.3%
N/A+33.7%C$64.93MC$27.87M27.20N/ANews Coverage

Related Companies and Tools


This page (TSE:APS) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners